Skip to main content

Table 2 Balance of covariates before and after matching

From: Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis

 

Unmatched*

Matched

Levosimendan (n = 48)

Control (n = 128)

p

Levosimendan (n = 48)

Control (n = 78)

p

Variable (mean)

 Age (years)

53.9

52.6

0.575

54.3

54.7

0.866

 Male (%)

62

65

0.692

0.62

0.65

0.785

 Potential for recovery

2.32

2.12

0.104

2.31

2.35

0.747

 SAPS-II

53.5

51.7

0.424

52.7

52.1

0.824

 SOFA

11.5

11.8

0.530

11.3

11.5

0.687

 LVEF (%)

18

20.2

0.241

18

17

0.690

 VA-ECMO duration (days)

10.6

6.5

<0.001

10.8

10.2

0.478

 Serum lactate level (mmol/L)

6.4

7.5

0.178

6.3

6.1

0.816

  1. Myocardial recovery potential: High 1 intermediate 2, Low 3 SAPS-II simplified acute physiology score, SOFA sequential organ failure assessment, LVEF left ventricular ejection fraction. Data are expressed as mean. The p value refers to a comparison between the levosimendan group and the control group. *Compared to the entire cohort (n = 200), the unmatched population had 176 patients since there were 24 patients with missing data on some of the variables used in the analysis